Patient-Derived Models of Cancer (PDMC) Program
The Patient-Derived Models of Cancer (PDMC) program, funded through PAR-16-344, developed and characterized patient-derived models to define the biological mechanisms that drive cancer phenotype and response to perturbations. The program tested and compared distinct patient-derived models generated from common patient samples with the objective of improving the understanding of the strengths and limitations of different patient-derived models as representatives of human tumors.
Additionally, the program performed systematic studies of patient-derived model parameters related to intrinsic tumor factors and microenvironmental pressures to explore fundamental cancer biology research questions. The goal of the PDMC was to improve patient-derived models for cancer biology research that may inform the development of novel cancer therapies.
PDMC Final Meeting
The last PDMC annual meeting was virtually held on Aug. 28, 2024. It highlighted the progress of the PDMC in the development and validation of patient-derived models for cancer biology. Additional information can be found in the meeting agenda.
NCI-Supported Resources Related to Patient-Derived Models
- PDX Finder – A comprehensive global catalogue of patient-derived xenograft (PDX) models and their associated data across resources
- NCI Patient -Derived Models Repository (PDMR) - A national repository of patient-derived models, including (PDXs), patient-derived tumor cell cultures and cancer associated fibroblasts, as well as patient-derived organoids
- PDXNet Portal – A database of PDX models, sequencing data, and PDX Minimum Information metadata tools generated by the PDXNet [inline link to NET Moonshot page] (which is funded by the Cancer Moonshot) for public use.
DCB Contact for the PDMC
For additional information about PDMC, please contact Dr. Konstantin Salnikow.
Past Projects